Double-Blinded Drug Discovery (DBD2)®

Why DBD2?

The 99% failure rate in modern pharmaceutical R&D demands an overhaul of the present model; everyone agrees. Stakeholders (patients, taxpayers, and legislators) are losing patience - and life - waiting for applied research to deliver effective new medicines. Applying deeper knowledge of the chemical biology of drug action is the missing link crucial for translating bench-top discoveries into cures.

  • LCGC's overarching mission is to improve translational research by connecting the exploratory excellence in academia with the chemical assets and development expertise in pharma to coalesce both their knowledge and know-how, harmonizing these disparate sectors with new synergy.

What Does DBD2 Provide?

LCGC provides university 'drug hunters' the best diversity and target-focused 'snapshots' from the millions of compounds owned by pharmas, pre-formatted on HTS-ready plates. We help optimize the assay parameters for successful application of the orthogonal-pooled screening (OPS) approach, which is one of LCGC's core technologies. Support extends to a point when the most potent and selective drug leads are in hand. The new drug leads discovered become a compelling basis for further collaboration between the institution and pharmaceutical company. Ultimately, this will enable deeper investigation into mechanisms of drug action and propel candidates more successfully to the clinic.


  • Technology Transfer Offices in academia and Business Development professionals in pharmas review and approve a unified 'Library Access Agreement' under a CDA
  • The PIs convey succinct (<1-page) target proposals via LCGC to Therapeutic Area Heads for approval
  • Pharmaceutical company's chemical diversity is interrogated 500% more efficiently
  • Target and institutional background IP are protected, as is pharma's chemical IP


  • De-risk innovative targets and translate target 'druggability' faster using fewer resources
  • Expand druggable space
  • Explore drug synergy
  • Accelerate technology licensing for commercialization
  • Repurpose drug candidates
  • Improved collaboration will help fulfill urgent unmet patient need





Image: Terra-cotta bas relief allegory of 'Industry and Invention' by Caspar Buberl
            Old Patent Office Great Hall, Washington, DC